Despite the death of its golden goose, AbbVie expects to achieve high single-digit compound annual sales growth to the end of ...

AbbVie (NYSE:ABBV) traded higher in the premarket on Friday after setting its 2025 earnings outlook in line with expectations ...

After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...

The carve-out acquisition will allow Bain to capitalize on the “promising signs for growth” in the Japanese life sciences ...

AbbVie has announced its second major takeover deal in the space of a few days, offering $8.7 billion to buy central nervous system drug specialist Cerevel Therapeutics, which spun out of Pfizer ...

North Chicago-based pharmaceutical giant AbbVie acquired the drug, called emraclidine, in an $8.7 billion acquisition of Cerevel Therapeutics last year. At the time, industry analysts predicted ...

Bain Capital, a global private investment firm, has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma ...

The North Chicago-based drugmaker is relying on newer treatments to make up for falling sales of Humira, its aging ...

The once-promising drug was a potential blockbuster for treating schizophrenia, and was the primary motive for the $8.7 billion Cerevel Therapeutics deal. Analysts have revised their long-term ...

According to DelveInsight’s epidemiology model, the total diagnosed prevalent cases of Parkinson’s disease were approximately ...

AbbVie’s market capitalisation grew by 14.8% in 2024, fueled by its acquisitions of ImmunoGen in February and Cerevel ...

Early this month, the Humira maker said that the non-cash charge reflected two failed mid-stage trials designed to evaluate Cerevel Therapeutics' lead drug, emraclidine, in schizophrenia.